Beren's Niemann-Pick drug Lembaz cleared by FDA

News
Beren Therapeutics

The FDA has approved Beren Therapeutics' Lembaz for Niemann-Pick disease type C (NPC), the first drug shown to extend survival in the ultra-rare lysosomal storage disorder.

Lembaz (adrabetadex), an intrathecally administered cyclodextrin-based therapy, has been cleared by the US regulator for use in children and adults with NPC that has emerged in infancy (before the age of six). The approval has been granted to Beren's Mandos subsidiary.

It is the first FDA-approved medicine to address the underlying cholesterol trafficking defect that causes NPC, according to Beren's chief executive, Jason Camm, who said the approval "reflects nearly two decades of determination from families, caregivers, clinicians, researchers, and advocates."

In NPC, the body cannot properly process cholesterol and other lipids inside cells. Over time, these substances accumulate, particularly in the brain, causing progressive neurological decline that in turn compromises movement, coordination, and the ability to swallow.

Two other drugs are already approved to treat NPC, namely Zevra Therapeutics' Miplyffa (arimoclomol) and IntraBio's Aqneursa (levacetylleucine), which address some of the neurological symptoms of the disorder but have not been shown to lengthen patients' lives. Moreover, both carry age and weight restrictions that limit access for the youngest and most seriously affected NPC patients, according to the FDA.

Another generically available drug originally developed for Gaucher disease, miglustat, is widely used off-label in the US for NPC, often given in combination with Miplyffa.

On average, individuals affected by this devastating disease only live for about 13 years, according to the FDA, which estimates that there are a few hundred people in the US living with NPC.

In trials involving 36 subjects with infantile-onset NPC and neurological complications, median survival time with Lembaz was 8.5 years, compared with 4.9 years in the control group, equivalent to a 55% reduction in the risk of death.

Camm said that Lembaz would be available at treatment sites across the US from next month. List pricing for the new product has not yet been announced. It will be interesting to see how Beren positions the drug against Miplyffa and Aqneursa, which are estimated to have an average cost of around $1 million and $700 million a year, respectively.

"For children and families with infantile-onset NPC, this long-awaited approval brings a new kind of hope for the future," said Heather Moran-Teal, executive director of the National Niemann Pick Disease Foundation (NNPDF).

"Lembaz represents an important step forward in the treatment of this devastating disease," she added. "For families who know how precious time can be, these encouraging survival findings carry profound meaning and hope for more time together."